.2019 Oct 7;216(10):2302-2315.

doi: 10.1084/jem.20191061. Epub 2019 Aug 14.

Risk of Zika microcephaly correlates with features of maternal antibodies

Davide F Robbiani^#¹, Priscilla C Olsen^#^{2 3}, Federico Costa^#^{4 5}, Qiao Wang^#⁶, Thiago Y Oliveira^#², Nivison Nery Jr⁷, Adeolu Aromolaran⁴, Mateus S do Rosário⁸, Gielson A Sacramento⁷, Jaqueline S Cruz⁷, Ricardo Khouri⁷, Elsio A Wunder Jr⁴, Adriana Mattos⁸, Bruno de Paula Freitas^{8 9}, Manoel Sarno⁵, Gracinda Archanjo⁸, Dina Daltro⁸, Gustavo B S Carvalho⁸, Kleber Pimentel⁸, Isadora C de Siqueira⁷, João R M de Almeida⁵, Daniele F Henriques¹⁰, Juliana A Lima¹⁰, Pedro F C Vasconcelos¹⁰, Dennis Schaefer-Babajew², Stephanie A Azzopardi¹¹, Leonia Bozzacco¹¹, Anna Gazumyan², Rubens Belfort Jr⁹, Ana P Alcântara¹², Gustavo Carvalho¹², Licia Moreira¹², Katiaci Araujo¹³, Mitermayer G Reis^{7 4 5}, Rebekah I Keesler¹⁴, Lark L Coffey¹⁵, Jennifer Tisoncik-Go^{16 17 18}, Michael Gale Jr^{16 17 18 19}, Lakshmi Rajagopal^{19 20 21}, Kristina M Adams Waldorf^{16 17 19 22}, Dawn M Dudley²³, Heather A Simmons²⁴, Andres Mejia²⁴, David H O'Connor²³, Rosemary J Steinbach²⁵, Nicole Haese^{26 27}, Jessica Smith²⁷, Anne Lewis²⁸, Lois Colgin²⁶, Victoria Roberts²⁵, Antonio Frias^{25 29}, Meredith Kelleher²⁵, Alec Hirsch^{26 27}, Daniel N Streblow^{26 27}, Charles M Rice¹¹, Margaret R MacDonald¹¹, Antonio R P de Almeida⁵, Koen K A Van Rompay^#^{14 15}, Albert I Ko^#^{7 4}, Michel C Nussenzweig^#^{30 31}

Affiliations

¹ Laboratory of Molecular Immunology, The Rockefeller University, New York, NY drobbiani@rockefeller.edu.
² Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
³ Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
⁴ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT.
⁵ Faculdade de Medicina and Instituto da Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
⁶ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
⁷ Instituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia, Brazil.
⁸ Hospital Geral Roberto Santos, Secretária da Saúde do Estado da Bahia, Salvador, Brazil.
⁹ Universidade Federal de São Paulo, São Paulo, Brazil.
¹⁰ Instituto Evandro Chagas, Ministério da Saúde Ananindeua, Pará, Brazil.
¹¹ Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
¹² Hospital Santo Amaro, Salvador, Bahia, Brazil.
¹³ Hospital Aliança, Salvador, Bahia, Brazil.
¹⁴ California National Primate Research Center, University of California, Davis, Davis, CA.
¹⁵ Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA.
¹⁶ Washington National Primate Research Center, Seattle, WA.
¹⁷ Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA.
¹⁸ Department of Immunology, University of Washington, Seattle, WA.
¹⁹ Department of Global Health, University of Washington, Seattle, WA.
²⁰ Department of Pediatrics, University of Washington, Seattle, WA.
²¹ Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA.
²² Department of Obstetrics and Gynecology, University of Washington, Seattle, WA.
²³ Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.
²⁴ Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI.
²⁵ Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Beaverton, OR.
²⁶ Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR.
²⁷ Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR.
²⁸ Pathology Services Unit, Division of Comparative Medicine, Oregon National Primate Research Center, Beaverton, OR.
²⁹ Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR.
³⁰ Laboratory of Molecular Immunology, The Rockefeller University, New York, NY nussen@rockefeller.edu.
³¹ Howard Hughes Medical Institute, The Rockefeller University, New York, NY.

^# Contributed equally.

PMID:31413072
PMCID: PMC6781003
DOI: 10.1084/jem.20191061

Risk of Zika microcephaly correlates with features of maternal antibodies

Davide F Robbiani et al. J Exp Med.2019.

.2019 Oct 7;216(10):2302-2315.

doi: 10.1084/jem.20191061. Epub 2019 Aug 14.

Authors

Affiliations

¹ Laboratory of Molecular Immunology, The Rockefeller University, New York, NY drobbiani@rockefeller.edu.
² Laboratory of Molecular Immunology, The Rockefeller University, New York, NY.
³ Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
⁴ Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT.
⁵ Faculdade de Medicina and Instituto da Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil.
⁶ Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
⁷ Instituto Gonçalo Moniz, Fundação Oswaldo Cruz/MS, Salvador, Bahia, Brazil.
⁸ Hospital Geral Roberto Santos, Secretária da Saúde do Estado da Bahia, Salvador, Brazil.
⁹ Universidade Federal de São Paulo, São Paulo, Brazil.
¹⁰ Instituto Evandro Chagas, Ministério da Saúde Ananindeua, Pará, Brazil.
¹¹ Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY.
¹² Hospital Santo Amaro, Salvador, Bahia, Brazil.
¹³ Hospital Aliança, Salvador, Bahia, Brazil.
¹⁴ California National Primate Research Center, University of California, Davis, Davis, CA.
¹⁵ Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA.
¹⁶ Washington National Primate Research Center, Seattle, WA.
¹⁷ Center for Innate Immunity and Immune Disease, University of Washington, Seattle, WA.
¹⁸ Department of Immunology, University of Washington, Seattle, WA.
¹⁹ Department of Global Health, University of Washington, Seattle, WA.
²⁰ Department of Pediatrics, University of Washington, Seattle, WA.
²¹ Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA.
²² Department of Obstetrics and Gynecology, University of Washington, Seattle, WA.
²³ Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI.
²⁴ Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI.
²⁵ Division of Reproductive and Developmental Sciences, Oregon National Primate Research Center, Beaverton, OR.
²⁶ Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR.
²⁷ Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, OR.
²⁸ Pathology Services Unit, Division of Comparative Medicine, Oregon National Primate Research Center, Beaverton, OR.
²⁹ Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR.
³⁰ Laboratory of Molecular Immunology, The Rockefeller University, New York, NY nussen@rockefeller.edu.
³¹ Howard Hughes Medical Institute, The Rockefeller University, New York, NY.

^# Contributed equally.

PMID:31413072
PMCID: PMC6781003
DOI: 10.1084/jem.20191061

Abstract

Zika virus (ZIKV) infection during pregnancy causes congenital abnormalities, including microcephaly. However, rates vary widely, and the contributing risk factors remain unclear. We examined the serum antibody response to ZIKV and other flaviviruses in Brazilian women giving birth during the 2015-2016 outbreak. Infected pregnancies with intermediate or higher ZIKV antibody enhancement titers were at increased risk to give birth to microcephalic infants compared with those with lower titers (P < 0.0001). Similarly, analysis of ZIKV-infected pregnant macaques revealed that fetal brain damage was more frequent in mothers with higher enhancement titers. Thus, features of the maternal antibodies are associated with and may contribute to the genesis of ZIKV-associated microcephaly.

PubMed Disclaimer

Figures

**Figure 1.**
**ZIKV neutralization capacity and ZEDIII binding are increased in mothers of microcephalic newborns. (a)** The collection period of the maternal sera of this study (November 2015 to February 2016) is indicated in gray alongside the incidence of exanthematic diseases (blue, left y axis) and neonates born with microcephaly (red, right y axis) per epidemiological week in Bahia. Adapted from Ministry of Health of Brazil (2017).(b) 160 maternal sera (43 cases with microcephaly and 117 controls) were screened at 1:1,000 dilution for neutralization of ZIKV RVPs. Neutralization was expressed as the reciprocal of the luciferase activity normalized to no serum control. Samples below the dotted line (open symbols) were considered nonneutralizing. Each symbol represents the average of triplicate values for each donor. All triangles are maternal sera from microcephaly cases, and triangles pointing down represent ZIKV cases confirmed either by RT-PCR or IgM ELISA on cord blood.(c) ZIKV neutralization potency was determined using RVPs. The neutralization capacity was expressed as the reciprocal of the serum dilution resulting in 50% inhibition compared with RVPs alone (NT₅₀). Each sample was evaluated in triplicate (n = 107, 40 cases with microcephaly and 67 controls). Three control samples that were identified as ZIKV neutralizers in the screening (panel b) were borderline in this assay and thus not plotted and omitted from further analysis.(d) IgG antibodies binding to ZEDIII were evaluated by ELISA. Binding was expressed as the reciprocal of the serum dilution resulting in 50% of maximal binding (BT₅₀). Each value represents the average of two independent assays (n = 103, 40 cases with microcephaly and 63 controls).(e) Correlation between ZIKV neutralization potency, expressed as NT₅₀, and ZEDIII binding, expressed as BT₅₀.(f) Serum antibodies binding to the ZEDIII lateral ridge were determined by antigen competition ELISA and expressed as ΔBT₅₀ (n = 103).(g) Correlation between ZIKV neutralization potency, expressed as NT₅₀, and ZEDIII lateral ridge binding, expressed as ΔBT₅₀.(h) IgG antibodies binding to UV-inactivated ZIKV were evaluated by ELISA. Optical densities were normalized by the control serum of a flavivirus naive individual vaccinated for YFV. Binding is expressed as the area under the curve (AUC) obtained in ELISA (n = 55, 27 microcephalies and 28 controls).(i) IgG antibodies binding to ZIKV NS1 protein were evaluated by ELISA. Optical densities were normalized as in panel h (n = 98, 39 cases with microcephaly and 59 controls). Each symbol represents an individual donor; black circles are from controls, and red triangles are from the microcephaly group. The P values in panels c, d, f, h, and i were determined with the Mann–Whitney test, and the mean and SD are shown. The P and ρ (rho) values for the correlation in panels e and g were determined with the Spearman test. *, P < 0.05; ***, P < 0.001. n.s., not significant.

**Figure 2.**
**Sera from mothers with microcephalic neonates have higher enhancing power and a higher peak enhancement titer. (a)** Enhancement of infection (fitted curves) by ZIKV RVPs is presented as the average of the fold change in luciferase activity of each group compared with control antibody (see Materials and methods). The thick lines represent control (n = 64) and microcephaly (n = 40) groups with ZIKV neutralizing activity, and thin lines represent samples that lack ZIKV neutralizing activity (empty symbols in Fig. 1 b). Sera were serially diluted and the enhancement of infection at each dilution for each group is shown. Standard errors are indicated in gray. The profile of the individual samples is shown in Fig. S2 a (n = 160).(b) Evaluation of the serum enhancing power. The enhancing power is defined as the fold increase of infection at peak enhancement titer for each serum sample (Fig. S1 a; Halstead, 2003).(c) Evaluation of the peak enhancement titer. The peak enhancement titer is the serum dilution at which maximum infection occurs for any tested sample (Fig. S1 a; Halstead, 2003).(d) Correlation between enhancing power and neutralization capacity, expressed as NT₅₀.(e) Correlation between peak enhancement titer and NT₅₀. The P values in panels b and c were determined with the Mann–Whitney test, and the mean and SD are shown. Symbols represent individual donors (n = 104). The P and ρ (rho) values for the correlations in panels d and e were determined with the Spearman test. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

**Figure 3.**
**Clustering analysis identifies groups with different retrospective risks of microcephaly in humans. (a)** Unsupervised hierarchical clustering of the log-normalized values for ZIKV RVP enhancement (ADE) combined with neutralization (NT₅₀,n = 104). Clusters are indicated in the first column, and the presence or absence of neonatal microcephaly is indicated in the second column in red or gray, respectively.(b) Histogram with the number of microcephaly cases (red) and controls (gray) in the three clusters. Statistical analysis of the relative risks was performed using the Fisher’s exact test (***, P < 0.0001).

**Figure 4.**
**Clustering analysis identifies groups with different retrospective likelihood of fetal brain damage in macaques. (a)** Unsupervised hierarchical clustering of the log-normalized values for ZIKV RVP enhancement (ADE) combined with neutralization (NT₅₀,n = 32). Clusters are indicated in the first column and the degree of fetal brain damage is indicated in the second column in red or gray, respectively.(b) Histogram with the number of cases with moderate to severe fetal brain pathology or fetal loss (red) and controls with undetectable to mild lesion (gray) in the four clusters. The statistical analysis of the relative risks was performed using the Fisher’s exact test (*, P < 0.05).(c) Evaluation of gestational day (GD) of infection, duration of viremia, and last GD with detectable viremia. Duration of viremia is the difference between last detectable viremia and day of infection. The P values were not significant (P > 0.05 as determined with the Mann–Whitney test), and the mean and SD are shown. Symbols represent individual animals (n = 32, except in middle and bottom panel, wheren = 31; see Table S2). n.s., not significant.

See this image and copyright information in PMC

Cited by

Adaptation to host cell environment during experimental evolution of Zika virus.
Grass V, Hardy E, Kobert K, Talemi SR, Décembre E, Guy C, Markov PV, Kohl A, Paris M, Böckmann A, Muñoz-González S, Sherry L, Höfer T, Boussau B, Dreux M.Grass V, et al.Commun Biol. 2022 Oct 21;5(1):1115. doi: 10.1038/s42003-022-03902-y.Commun Biol. 2022.PMID:36271143Free PMC article.
Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya.
Barsosio HC, Gitonga JN, Karanja HK, Nyamwaya DK, Omuoyo DO, Kamau E, Hamaluba MM, Nyiro JU, Kitsao BS, Nyaguara A, Mwakio S, Newton CR, Sang R, Wright D, Sanders EJ, Seale AC, Agoti CN, Berkley JA, Bejon P, Warimwe GM.Barsosio HC, et al.Wellcome Open Res. 2019 Nov 15;4:179. doi: 10.12688/wellcomeopenres.15568.1. eCollection 2019.Wellcome Open Res. 2019.PMID:32175480Free PMC article.
Microcephaly and Associated Risk Factors in Newborns: A Systematic Review and Meta-Analysis Study.
Melo NL, Sousa DF, Laporta GZ.Melo NL, et al.Trop Med Infect Dis. 2022 Sep 24;7(10):261. doi: 10.3390/tropicalmed7100261.Trop Med Infect Dis. 2022.PMID:36288003Free PMC article.Review.
Effect of prior Zika and dengue virus exposure on the severity of a subsequent dengue infection in adults.
Valencia BM, Sigera PC, Weeratunga P, Tedla N, Fernando D, Rajapakse S, Lloyd AR, Rodrigo C.Valencia BM, et al.Sci Rep. 2022 Oct 14;12(1):17225. doi: 10.1038/s41598-022-22231-y.Sci Rep. 2022.PMID:36241869Free PMC article.
A single nonsynonymous mutation on ZIKV E protein-coding sequences leads to markedly increased neurovirulence in vivo.
Liu Z, Zhang Y, Cheng M, Ge N, Shu J, Xu Z, Su X, Kou Z, Tong Y, Qin C, Jin X.Liu Z, et al.Virol Sin. 2022 Feb;37(1):115-126. doi: 10.1016/j.virs.2022.01.021. Epub 2022 Jan 21.Virol Sin. 2022.PMID:35234632Free PMC article.

See all "Cited by" articles

References

1. Adams Waldorf K.M., Stencel-Baerenwald J.E., Kapur R.P., Studholme C., Boldenow E., Vornhagen J., Baldessari A., Dighe M.K., Thiel J., Merillat S., et al. . 2016. Fetal brain lesions after subcutaneous inoculation of Zika virus in a pregnant nonhuman primate. Nat. Med. 22:1256–1259. 10.1038/nm.4193 - DOI - PMC - PubMed
1. Adams Waldorf K.M., Nelson B.R., Stencel-Baerenwald J.E., Studholme C., Kapur R.P., Armistead B., Walker C.L., Merillat S., Vornhagen J., Tisoncik-Go J., et al. . 2018. Congenital Zika virus infection as a silent pathology with loss of neurogenic output in the fetal brain. Nat. Med. 24:368–374. 10.1038/nm.4485 - DOI - PMC - PubMed
1. Aldo P., You Y., Szigeti K., Horvath T.L., Lindenbach B., and Mor G.. 2016. HSV-2 enhances ZIKV infection of the placenta and induces apoptosis in first-trimester trophoblast cells. Am. J. Reprod. Immunol. 76:348–357. 10.1111/aji.12578 - DOI - PubMed
1. Andrade D.V., and Harris E.. 2017. Recent advances in understanding the adaptive immune response to Zika virus and the effect of previous flavivirus exposure. Virus Res. 10.1016/j.virusres.2017.06.019 - DOI - PMC - PubMed
1. Barba-Spaeth G., Dejnirattisai W., Rouvinski A., Vaney M.-C., Medits I., Sharma A., Simon-Lorière E., Sakuntabhai A., Cao-Lormeau V.-M., Haouz A., et al. . 2016. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 536:48–53. 10.1038/nature18938 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide
Actions
- Search in PubMed
- Search in Nucleotide

Related information

MedGen

Movatterモバイル変換

Account

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Full text links

Actions

Share

Risk of Zika microcephaly correlates with features of maternal antibodies

Affiliations

Risk of Zika microcephaly correlates with features of maternal antibodies

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical